Clinical evaluation of allogeneic adipose tissue-derived stem cells for the treatment of osteoarthritis secondary to hip dysplasia in dogs

ABSTRACT: This study assessed the efficacy of an intra-articular injection of allogeneic adipose tissue-derived from mesenchymal stem cells (AD-MSCs) for the treatment of hip dysplasia in dogs. The study group included 12 otherwise healthy dogs of different breeds, ages, weights, and degrees of hip dysplasia diagnosed using radiography. An orthopedic assessment was performed on all dogs before and at 30, 60, and 90 days after infusion of AD-MSCs(2 × 106cells). On the same days, each dog’s owner answered a questionnaire based on theHelsinkiChronic Pain Index. The data were converted to ordinal data based on the score for each variable, and the Friedman test for multiple comparisons was used to verify the results. Compared with the corresponding values on day 0, orthopedic and gait assessments and owners’ reported pain indexes improved over the 90-day observation period. These results suggested that treatment with allogeneic AD-MSCs significantly reduced the clinical signs associated with hip dysplasia during the study period. However, long-term studies are needed to determine the optimal therapeutic protocol for routine clinical use of AD-MSCs in hip dysplasia.

摘要：本研究评估了异体脂肪源性间充质干细胞（adipose tissue-derived mesenchymal stem cells，AD-MSCs）关节腔内注射治疗犬髋关节发育不良的疗效。研究组纳入12只无其他基础疾病的健康犬，涵盖不同品种、年龄、体重，且经X线影像学检查确诊为不同程度的髋关节发育不良。所有受试犬在输注AD-MSCs（2×10⁶个细胞）前，以及输注后30、60、90天均接受骨科评估。在上述相同时间节点，每只犬的主人需完成基于赫尔辛基慢性疼痛指数（Helsinki Chronic Pain Index）的调查问卷。研究人员将各变量得分转换为有序数据，并采用弗里德曼多重比较检验对实验结果进行验证。与第0天的对应数值相比，在90天的观察周期内，骨科与步态评估结果以及主人报告的疼痛指数均得到显著改善。本研究结果提示，异体AD-MSCs治疗可在试验期间有效缓解犬髋关节发育不良相关临床症状。不过，仍需开展长期研究以确定AD-MSCs用于犬髋关节发育不良临床常规治疗的最优方案。